CRESCENT BIOPHARMA, INC. — Director's Dealing 2017

May 30, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2017-05-25

Reporting Person: Thackray Helen M. (SVP Clinical Development, CMO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-05-25	Common Stock	S	2000	$15.57	Disposed	152615	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b-5 trading plan adopted by the reporting person on May 31, 2016.